TRIM58 is a member of the TRIM protein family, which possess with E3 ubiquitin ligase activities. Studies have revealed that low expression of TRIM58 plays key roles, has been implicated in the tumor progression of tumor formation due to its reduced expression. However, its role in regulating the stemness of breast cancer stem cells (CSCs) remains unexplored. Here, we found that TRIM58 was underexpressed in TNBC tissues and cells compared to adjacent mucosa tissue, and its downregulation was significantly associated with shorter survival. Overexpression of TRIM58 reduced the proportion of CD44 + /CD24- cells, upregulated differentiation genes, and inhibited stemness-related gene expression in TNBC CSCs. In vitro and in vivo experiments revealed that TRIM58 overexpression in CSCs suppressed tumor sphere formation and tumorigenic capacity. Co-IP results indicated direct interaction between TRIM58 and MYH9, with TRIM58 inducing MYH9 degradation via ubiquitination in differentiated cells. Label-free quantitative proteomics identified GRK3 and Hippo-YAP as downstream targets and signaling pathways of MYH9. TIMER database analysis, immunohistochemistry, western blotting, DNA-protein pulldown experiments, and dual luciferase reporter assays demonstrated that MYH9 regulated GRK3 transcriptional activation in CSCs. In conclusion, elevated TRIM58 expression in CSCs downregulates MYH9 protein levels by promoting ubiquitin-mediated degradation, thereby inhibiting downstream GRK3 transcription, inactivating the YAP stemness pathway, and ultimately promoting CSC differentiation.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-024-00780-wDOI Listing

Publication Analysis

Top Keywords

trim58
9
breast cancer
8
cancer stem
8
stem cells
8
cells
5
cscs
5
myh9
5
trim58 downregulation
4
downregulation maintains
4
maintains stemness
4

Similar Publications

Objective: To identify key genes associated with the prognosis of non-small cell lung cancer (NSCLC) through bioinformatics analysis and experimental validation, exploring the expression of the TRIM58 gene and its potential effect as a tumor suppressor.

Methods: In this study, differentially expressed genes (DEGs) and differentially methylated genes (DMGs) related to lung adenocarcinoma and lung squamous cell carcinoma were selected from the TCGA dataset, with the Limma package in R software used for further filtering and intersection, followed by the assessment of the relationship between these genes and NSCLC prognosis using log-rank tests and univariate Cox regression analysis. Meanwhile, six clinical NSCLC cancer and adjacent tissue samples were collected, along with the detection of TRIM58 mRNA and protein levels using RT-PCR and Western blot.

View Article and Find Full Text PDF

This study investigated whether the neddylation inhibitor MLN4924 induces aberrant DNA methylation patterns in acute myeloid leukemia and contributes to the reactivation of tumor suppressor genes. DNA methylation profiles of Kasumi-1 and KU812 acute myeloid leukemia cell lines before and after MLN4924 treatment were generated using the 850K Methylation BeadChip. RNA sequencing was used to obtain transcriptomic profiles of Kasumi-1 cells.

View Article and Find Full Text PDF

Redirecting E3 ubiquitin ligases for targeted protein degradation with heterologous recognition domains.

J Biol Chem

January 2025

Department of Pediatrics, Dana Farber/Boston Children's Hospital Cancer and Blood Disorder Center, Boston, Massachusetts, USA; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA; Howard Hughes Medical Institute, Boston Children's Hospital, Boston, Massachusetts, USA. Electronic address:

Targeted protein degradation (TPD) mediated by proteolysis targeting chimeras or molecular glues is an emerging therapeutic strategy. Despite greater than 600 E3 ligases and their associated components, a limited number have been deployed in TPD. Those commonly used include cereblon and von Hippel-Lindau tumor suppressor (VHL), which is expressed widely and for which high affinity ligands are available.

View Article and Find Full Text PDF

Comment on, "Expression of decitabine-targeted oncogenes in meningiomas in vivo".

Neurosurg Rev

September 2024

Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai-77, Tamil Nadu, India.

The study by Canisius et al. (2022) explores the expression of decitabine-targeted oncogenes (TRIM58, FAM84B, ELOVL2, DIO3) in meningiomas, aiming to evaluate decitabine's therapeutic potential for high-grade tumors. Using immunohistochemical staining and RT-PCR in over 100 patient samples, the authors found significant correlations between oncogene expression and tumor grade, with elevated ELOVL2 levels being linked to tumor recurrence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!